AbbVie Inc.'s late-to-the-stage anti-IL23 inhibitor risankizumab has hit all co-primary and ranked secondary endpoints in its fourth and final Phase III study in psoriasis, highlighting both the Humira successor's potential clinical profile and the prospect of it coming under heavy pricing pressure.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?